Integrative Prognostic Modeling of Breast Cancer Survival with Gene Expression and Clinical Data
Robert Amevor*, Emmanuel Kubuafor, Dennis Baidoo, Junaidu Salifu, Koshali Muthunama Gonnage, Onyedikachi Joshua Okeke · 2025
Read Integrative Prognostic Modeling of Breast Cancer Survival with Gene Expression and Clinical Data by Robert Amevor*, Emmanuel Kubuafor, Dennis Baidoo, Junaidu Salifu, Koshali Muthunama Gonnage, Onyedikachi Joshua Okeke (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2508-16740.txt.
Introduction
Robert Amevor and co-authors build a tool in 2025 to predict how long breast cancer patients will live. Good forecasts help doctors sort patients by risk and plan care that fits each case. The team mixed gene data with standard clinical facts for 1,867 patients from the METABRIC group.
From thousands of genes, the model kept 75 factors: 70 genes and five clinical items such as tumor size, stage, and age. The mixed model scored far better than a clinical-only model on standard accuracy checks. A forest model then backed up the top genes and caught curved effects the first model could miss. The authors say the blend gives a firm base for forecasts tuned to each patient, though care use still needs care and more tests.
Catalog record
| CREATOR | Robert Amevor*, Emmanuel Kubuafor, Dennis Baidoo, Junaidu Salifu, Koshali Muthunama Gonnage, Onyedikachi Joshua Okeke |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2508-16740
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Integrative Prognostic Modeling of Breast Cancer Survival with Gene Expression and Clinical Data Robert Amevor*, Emmanuel Kubuafor, Dennis Baidoo, Junaidu Salifu, Koshali Muthunama Gonnage, Onyedikachi Joshua Okeke Abstract *Corresponding author: [email protected] Abstract Background: Accurate survival prediction in breast cancer is essential for patient stratification and personalized therapy. Integrating gene expression data with clinical factors may enhance prognostic performance and support precision medicine. Objective: To develop an integrative survival prediction model combining clinical variables and gene expression signatures in breast cancer, and to assess the relative contribution of each component using penalized Cox regression and machine learning. Methods: We analyzed 1,867 patients from the METABRIC cohort with clinical annotations and microarray-based gene expression profiles. The top 5,000 most variable genes (median absolute deviation) were retained. Elastic Net–penalized Cox regression identified 75 predictors (70 genes and 5 clinical variables: tumor size, stage, surgery type, age at diagnosis, and Nottingham Prognostic Index). Model performance was evaluated with Harrell’s concordance index (C-index) and 36-month time-dependent AUC. Random Survival Forests (RSF) were trained on the top 20 genes to assess nonlinear effects and validate variable importance. Gene expression patterns were visualized using PCA and heatmaps. Results: The integrative Cox model achieved a C-index of 0.922 and a 36-month AUC of 0.94, outperforming clinical-only (C = 0.64). RSF analysis confirmed prognostic contributions of top genes (e.g., OR2T27, TBATA, LINC01165, SLC10A4), yielding a 36-month AUC of 0.88. PCA and heatmaps revealed distinct molecular profiles across risk groups. Conclusions: Integrating gene expression signatures with clinical variables substantially improves survival prediction in breast cancer. This framework offers a robust foundation for individualized prognostic assessment and may inform clinical decision-making and trial design. Keywords :Breast cancer, gene expression, Elastic Net, Cox model, Random Survival Forests, integrative modeling, survival prediction. 1 Introduction Breast cancer remains the most commonly diagnosed cancer among women worldwide, accounting for over 2.3 million new cases and 685,000 deaths annually as of 2020 Siegel et al. 2023 ; Sung et al. 2021 . Despite advances in early detection and systemic therapies, survival outcomes remain heterogeneous even among patients within the same clinical stage or molecular subtype. This heterogeneity underscores the urgent need for more accurate and individualized prognostic tools that go beyond traditional staging to better inform treatment decisions and patient counseling. Historically, prognostic models for breast cancer have relied on clinicopathologic variables such as tumor size, nodal status, histological grade, and hormone receptor expression Goldhirsch et al. 2013 . While these factors provide valuable information, they often fall short in accounting for the biological complexity of breast tumors. High-throughput technologies, particularly gene expression profiling, have significantly advanced our understanding of tumor biology. The seminal work by Perou et al. 2000 introduced the concept of molecular subtypes in breast cancer, demonstrating that tumors of similar histology can differ profoundly at the genomic level . Building on this molecular foundation, commercial assays such as Oncotype DX and MammaPrint have been clinically validated to assess recurrence risk and guide chemotherapy use in early-stage breast cancer Sparano et al. 2018 ; Paik et al. 2004 . However, these tools are limited by fixed gene panels, high costs, and potential lack of generalizability across diverse populations. Consequently, there has been a growing interest in developing integrative prognostic models that incorporate clinical, genomic, and immune-related variables using advanced machine learning techniques Varnier et al. 2021 ; Hussain et al. 2024 ; Sammut et al. 2022 . Elastic Net penalized Cox regression is particularly suitable for high-dimensional omics data as it performs variable selection while handling multicollinearity among gene features Zou and Hastie 2005 . Additionally, Random Survival Forests (RSF) offer a non-parametric alternative that can capture complex nonlinear interactions without stringent modeling assumptions Ishwaran et al. 2008 ; Boulesteix et al. 2012 . These approaches have been increasingly used in cancer prognostic modeling and have demonstrated robust performance in both internal and external validation settings Wang et al. 2024 ; Hao et al. 2021 . In this study, we aimed to develop an integrative prognostic model for breast cancer survival by combining clinical features with gene expression signatures, including immune-related markers. We applied Elastic Net Cox regression for gene selection and RSF for non-linear modeling and variable importance assessment. Visualization methods, including heatmaps and principal component analysis (PCA), were used to explore molecular patterns associated with risk stratification. Our goal was to evaluate whether this integrative modeling framework could outperform models using clinical or gene-only inputs, thereby supporting more personalized and biologically informed patient care. 2 Methods 2.1 Data Sources We utilized a publicly available cohort (BRCA METABRIC) comprising approximately 1,979 breast cancer patients with matched clinical data and gene expression profiles derived from microarray technology. The dataset included relevant clinical variables such as lymph node status, tumor size, type of breast surgery, and overall survival time and status. Gene expression values were log-transformed and standardized across samples. 2.2 Data Preprocessing Clinical covariates with missing values were imputed using multiple imputation by chained equations (MICE), implemented via the mice R package. Each incomplete variable was imputed using a fully conditional specification appropriate to its type (e.g., predictive mean matching for continuous variables and logistic regression for binary variables). Five imputed datasets were generated, and results were pooled according to Rubin’s rules. To reduce noise and computational burden, genes with low variance across samples were excluded. The top 5,000 most variable genes—based on median absolute deviation (MAD)—were retained for downstream modeling, a commonly used threshold balancing dimensionality reduction and biological signal retention. 2.3 Feature Selection with Elastic Net Penalized Cox Model To identify a parsimonious subset of prognostic genes, we applied the Elastic Net regularization method within a Cox proportional hazards framework. The Elastic Net combines both Lasso ( \ell_{1} ) and Ridge ( \ell_{2} ) penalties, promoting sparsity while handling multicollinearity among predictors. The optimization objective is given by: \hat{\beta}=\arg\min_{\beta}\left\{-\ell(\beta)+\lambda\left(\alpha\lVert\beta\rVert_{1}+\frac{1-\alpha}{2}\lVert\beta\rVert_{2}^{2}\right)\right\} where \ell(\beta) is the partial log-likelihood of the Cox model, \lambda is the regularization parameter controlling overall penalty strength, and \alpha balances the contribution of the Lasso and Ridge penalties. To balance the benefits of L1 (Lasso) and L2 (Ridge) regularization, we set the Elastic Net mixing parameter \alpha=0.5 using the glmnet R package, giving equal weight to both penalties. This value was selected to promote both sparsity (variable selection) and grouping effects among correlated predictors, which are common in gene expression data. While values of \alpha ranging from 0.1 to 0.9 were explored in preliminary analysis, the overall model performance—measured by cross-validated partial likelihood deviance and stability of selected features—was comparable across this range. Hence, \alpha=0.5 was adopted as a pragmatic default to balance model interpretability and robustness, consistent with previous integrative modeling studies in high-dimensional omics data. A sequence of candidate \lambda values was generated on a log scale, and the optimal value was selected via 10-fold cross-validation based on the partial likelihood deviance. This approach ensured that the model selected a robust and interpretable set of gene predictors with optimal predictive performance. Model performance was further evaluated using the time-dependent concordance index (C-index) and time-dependent area under the curve (AUC) at clinically relevant time points (12, 24, and 36 months), computed across folds. The final model was refit using the optimal \lambda on the full dataset. 2.4 Multivariable Cox